Proteomic clocks link accelerated aging to higher risk of death and disease

An analysis of 17,473 participants links the acceleration of age measured with blood proteins to a higher risk of mortality, cardiovascular diseases, dementia, and various types of cancer.

• The study evaluated several proteomic clocks based on plasma samples and followed participants for up to 28 years.
• The so-called global age gap was associated with smoking, alcohol consumption, and physical inactivity.
• Organ-specific clocks showed stronger links to lung, kidney, and stomach cancers.

The age marked on the calendar does not always match the biological state of the organism. An analysis of proteomic clocks, built from proteins present in the blood, found that an estimated age higher than chronological age is related to a greater risk of mortality and various diseases associated with aging.

The study examined 17,473 participants from the European Prospective Investigation into Cancer and Nutrition and followed their evolution for up to 28 years. The analysis was also contrasted with data from the Whitehall II study to verify whether the observed associations were repeated in another population. The article can be consulted in "Associations of proteomic age with mortality and incident disease."

What proteomic clocks measure

Proteomic clocks are statistical models that use protein patterns to estimate biological age. Instead of merely counting the years since birth, they seek to summarize molecular signals related to the functioning of the organism and compare them with each person's chronological age.

In this case, researchers studied clocks based on measurements of plasma proteins obtained through the SomaScan platform. The analysis included both a global indicator, capable of combining different proteomic clocks, and tools designed to reflect the state of specific organs.

The difference between the age estimated by the clock and the actual age is known as the age gap or acceleration. When the clock shows an age greater than the chronological age, that deviation alone does not equate to a diagnosis, but it can serve as a statistical marker of greater vulnerability to diseases and death.

The value of these instruments, therefore, does not lie in issuing an individual judgment about how long a person will live. Their main utility in the study was to compare large groups, observe risk patterns, and build a reference for future research on interventions that may modify the pace or state of degenerative aging.

Risks associated with acceleration

The global age gap was related to several lifestyle factors, including smoking, alcohol consumption, and physical inactivity. These associations do not prove that a proteomic clock identifies a single cause nor do they allow attributing each outcome to a single habit, but they show that molecular signals capture part of the deterioration linked to known exposures.

Researchers also found that greater acceleration was associated with an increased risk of mortality from all causes. The link extended to cardiovascular diseases and dementia, two groups of conditions that often account for a significant portion of the disease burden related to age.

The analysis also identified associations with liver cancer, upper aerodigestive tract cancer, lung cancer, and kidney cancer. The result does not mean that the proteomic clock can replace a clinical test or detect a tumor by itself, although it does support its potential use as a biomarker of widespread risk.

The available information also indicates that organ-specific clocks provided narrower signals for certain tumors. Lung, kidney, and stomach cancers showed stronger associations with the age gaps corresponding to those organs, a finding that opens the door to more detailed assessment models than a single global measure.

Scope and Limitations of the Finding

One of the central points of the study was to compare the predictive capacity of proteomic clocks with that of classic lifestyle-related risk factors. For mortality, the performance of the clocks was comparable to those traditional indicators, suggesting that blood proteins may condense relevant information about overall health status.

However, correlation does not equate to causation. The presence of an advanced proteomic age alongside more diseases does not demonstrate that the clock causes deterioration, nor does it guarantee that reducing the score through an intervention will automatically decrease the risk of death or cancer.

The summary of the work itself indicates that these clocks do not significantly improve the quality of correlation when compared to lifestyle indicators. This observation imposes caution against the idea that a molecular measurement could replace basic information about physical activity, alcohol consumption, smoking, or other relevant factors.

It is also important to distinguish between a research tool and a test available for everyday medical decisions. The study provides population evidence and a reference baseline, but the consulted material does not present a protocol for patients to individually interpret their results nor establish treatments based on accelerated aging.

Why Organ Measurements Matter

A global clock summarizes multiple signals but may obscure differences between body systems. A person might show a moderate deviation in the overall indicator while simultaneously presenting a more marked gap in the set of proteins associated with a particular organ, although the study does not convert that possibility into a diagnostic tool.

The associations observed with lung, kidney, and stomach cancer were more intense when compared to the specific clocks of the corresponding organs. This coincidence offers a clue to investigate whether certain proteomic patterns reflect local processes, systemic responses, or a combination of both mechanisms.

The ability to separate signals by organs may be especially useful for designing follow-up studies. Instead of merely asking whether an intervention reduces total biological age, researchers could examine whether it differently modifies signals related to the heart, brain, lungs, kidneys, or liver.

Still, the result should be read as an epidemiological association that needs further validation. Replication in Whitehall II reinforces the consistency of the analysis but does not eliminate the need to verify how these clocks behave in other populations and under specific interventions.

What This Line of Research Could Contribute

The prolonged follow-up of the European cohort allows for the observation of incident diseases and mortality over a wide period, which is important when studying processes that develop over decades. The inclusion of 24 chronic diseases also offers a broader view than an analysis focused on a single diagnosis.

These data may serve as a reference for evaluating treatments, habit changes, or other interventions aimed at influencing degenerative aging. If a strategy consistently modifies age gaps and is subsequently associated with better clinical outcomes, researchers would have an additional clue to study its impact.

Future utility will depend on whether the clocks are reproducible, interpretable, and sufficiently accurate to add information beyond already known risk factors. It will also be necessary to clarify when a high score reflects a reversible process, an undetected disease, or simply biological variations that will not lead to an adverse outcome.

For now, the main conclusion is more cautious: proteomic clocks appear to be promising biomarkers of the widespread risk of age-related diseases. Their potential lies in improving research and statistical stratification, not in turning an age difference into a definitive individual prognosis.

This analysis reinforces the idea that measuring aging requires observing biological signals, but also reminds us that no isolated metric replaces clinical evaluation or monitoring of known risk factors.

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.